The High Cost of the Shutdown

 

Sooner or later the bill must be paid. America is now paying the bill for the voluntary shutdown of the American economy to control the spread of the Covid-19 virus. The actual price of that bill is still being determined, and won’t really be known for months, but the cost in human lives is being felt now.

The unemployment figures are the starkest evidence of the high price. Unemployment reached 14.7% this week and is expected to go higher. According to The Wall Street Journal, 20.5 million workers were lost from the work force in the month of April, erasing a decade of job gains in a single month. This is the worst jobless rate in the U.S. since the Great Depression of the 1930s.

These are not just numbers. They reflect the impact of the shutdown, not the virus itself, on American lives. The damage to these lives will be felt not only in lost wages, but in declining health through depression, drug and alcohol addiction, delayed healthcare, and even suicide. CVS executives warned this week that delayed care could lead to a surge of non-corona virus related health problems including cancers undiagnosed and illnesses left untreated. There is widespread evidence of parents delaying vaccinations for their children, which will also have unintended consequences.

On March 30 I called for America to get back to work (Corona Virus Update: Time to Go Back to Work, America.) At that time President Trump was hoping to reopen the economy by Easter, which was April 12. But pressure from the media, Democratic leaders, and the Corona Virus Task Force physicians forced Trump to delay reopening until May. This may have saved some lives in the short run, but certainly increased the economic hardship in the long run.

Not everyone understands the reality of this situation or else chooses to ignore it. The Wall Street Journal editorial board calls out the media’s role in this misinformation. “Much of the media continue to treat the economic destruction as a sideshow and present a false choice between saving lives and jobs. But this is the fastest jobs collapse in modern history. The Great Depression drove millions of Americans into poverty and caused many suicides, and there’s a substantial risk this could happen again.”

The shutdown was a voluntary interruption of the economy by the Trump administration to “slow the spread” of the virus and thus preserve our ability to handle a surge in demand for healthcare facilities, especially hospital intensive care beds and ventilators. This was achieved without any reports of hospital bed or ventilator rationing. It was never intended to prevent widespread infection of the population, which cannot be achieved without an effective vaccine.

There is actually some benefit to widespread infection, as long as it does not overwhelm our ability to respond with appropriate medical care for all who need it. As more and more of the population is exposed to the virus, and develops antibodies against it, the nation will achieve “herd immunity.” This will protect our most vulnerable Americans and reduce the chances of future Covid-19 epidemics until an effective vaccine is developed. The goal should be developing “herd immunity” without overwhelming our healthcare system.

As America slowly re-opens, decisions are being made all across our nation that will have profound impact on the lives of millions of Americans. The choice cannot be strictly between what’s best to limit the spread of the virus or what’s best for the economy. It must be a combination of what’s best for both. To ignore either concern will cause unnecessary suffering of one kind or another.

WSJ summarizes the situation: “The tradeoff isn’t between lives and livelihoods. The policy goal has to be to protect both as much as possible. Deploy more personal protective equipment, greatly increase testing, build surge capability to handle flare-ups, and isolate society’s most vulnerable to keep hospitals from getting overwhelmed. But for heaven’s sake reopen the economy so we don’t consign millions to years of poverty.”

Brain Supplements: Do They Really Work?

Like most adults over the age of 65, my wife and I have noticed some difficulty recalling names as we get older. We all worry that our minds will fail us and wonder if there is any validity to those claims about dietary supplements to improve our brain function. Who hasn’t wondered if those ubiquitous ads about Prevagen, the jelly-fish supplement, have any truth to them? After all, they claim to be “clinically proven” to improve brain function.

To answer these questions, I decided to do some research. The first thing I learned is that there is big money to be made out there selling brain supplements. By some estimates, the dietary supplement market is expected to reach $350 Billion by 2026. With that amount of money up for grabs, you can be sure there is a lot of competition – and a lot of back-stabbing by competitors.

The first whole page of my Google search came up with competing claims for one brain supplement against another. One site listed their top five supplements while the next listed their top five – and all the reasons why the other site’s top five were bogus. There was an alarming lack of agreement – and a shocking lack of scientific credentials from those making their recommendations. It was obvious I would need to dig deeper to find the truth.

Deeper research was rewarding – at least to dispel the false claims of the brain supplement manufacturers and their fans. First of all, I learned that the makers of Prevagen, the most widely advertised brain supplement, has been warned by the Federal Trade Commission and the New York State’s attorney general about making deceptive claims in 2017. “The marketers of Prevagen preyed on the fears of older consumers experiencing age-related memory loss,” said Jessica Rich, director of the FTC’s Bureau of Consumer Protection. “But one critical thing these marketers forgot is that their claims need to be backed up by real scientific evidence.”

A 2019 article from the Journal of the American Medical Association (JAMA), written by neurologists and dementia researchers at The University of California San Francisco, says there is no known dietary supplement that prevents cognitive decline for dementia. I found support for this viewpoint in other scientific literature as well as the Harvard Medical School Health Blog. An excellent review of the literature can be found from the Department of Geriatrics and Palliative Medicine, Mt. Sinai School of Medicine in New York.

The key statement from this review can be found in the Abstract: “Currently, there are no effective preventive strategies for cognitive decline.”  However, there is reason for concern with the use of dietary supplements because of their potential interaction with other medications. The Abstract goes on to warn: “Considering the insufficient evidence for their efficacy, potential for interaction with other therapies and costs to patients, physicians should be aware of the use of dietary supplements among their patients so that they can advise their patients on the potential benefits and harms.”

The Most Commonly Used Supplements

The reviewers commented on the most commonly used supplements, their efficacy, and potential side effects:

  • Ginkgo biloba– Studies have found that there was no difference in dementia incidence in all participants or in the rate of progression to dementia in participants when compared to the placebo group. Ginkgo biloba may interact with antiplatelet or anticoagulation medications which may lead to bleeding. The incidence of hemorrhagic strokes in the ginkgo biloba group was twice as high as placebo.
  • Vitamins B6, B9, B12 – Supplementation with B vitamins did not demonstrate any improvement in cognitive performance compared with placebo. However, there was an increased incidence of depression in the high-dose supplement group.
  • Vitamin E– There was no difference in cognitive performance between the Vitamin E treated group and placebo. There was some evidence to suggest that higher intake diets of Vitamin E may provide some protection against development of dementia when compared to low dietary intake of Vitamin E but this was not found in the studies uses Vitamin E supplementsto diet. Further study of this is needed.
  • W-3 Fatty Acids – Studies of these unsaturated fatty acids (PUFA) have been inconsistent but to date there is no study that has found any association between fish or w-3 fatty acids demonstrating better cognitive function or less cognitive decline in over 6 years follow-up.
  • Vitamins A and C – Evidence for the protective effects of Vitamins A and C against cognitive decline, impairment, or dementia is inconsistent and insufficient to recommend Vitamin A or C supplementation for cognitive health.
  • Vitamin D –To our knowledge, there are no available randomized control trials of Vitamin D supplementation for the enhancement of cognition or prevention of cognitive decline and dementia.
  • Phospholipids:phosphatidylserine and phosphatidylcholine –
    These phospholipids are the second most frequently endorsed substance for older adults with memory complaints by proprietorsof dietary supplements. In a recent small study of 157 participants, there was some suggestion of better cognitive performance in 15 weeks’ follow-up when compared with placebo in a group using phosphatidylserine, a w-3 long-chain (PUFA) and longer-chain decosahexaenoic acid (DHA) plus eicosapentaenoic acid (PS-DHA). Larger trials are needed confirm these findings before recommending the use of phospholipid supplementation.
  • Ginseng –For adults with cognitive impairment or dementia, there were no randomized, placebo-controlled trials assessing the effect of ginseng. Further large randomized controlled trials are needed.

 

Conclusions

I conclude with this quote from the Mt. Sinai School of Medicine review: “There is little evidence today to suggest any benefit to the use of dietary supplements to improve cognitive function or delay the progression of dementia. The exception may be in Vitamin E supplementation among older adults with moderate dementia, but its harmful effects must be considered. Until further studies are available to better demonstrate the benefits of supplements on cognition, encouraging a balanced diet that contains essential vitamins and nutrients may reap more health benefits.”

Remdesivir to the Rescue

The panic over the Covid-19 virus is diminishing and America is beginning to reopen again for business and social interaction. But the risk remains that you may still get infected if you’re exposed to someone contaminated with the virus and you fail to take the necessary precautions.

Most people who do contract the virus will have minimal symptoms and recover uneventfully. But a small but significant few will get seriously ill and some will die, mostly those with significant co-morbidities such as heart disease, diabetes, and respiratory illnesses.

Only two developments can change that scenario: an effective drug to treat the virus, or even better, an effective vaccine to prevent viral infection in the first place. Absent these two developments, the virus will continue to run its course, wreaking havoc on our lives and our economy.

Multiple pharmaceutical companies are working hard now to develop an effective vaccine and there are hopeful signs of one by early next year. But the big news this past week is the FDA approval of remdesivir as an effective treatment for those with serious Covid-19 infection. This is great news and should be a huge encouragement to all Americans, as well as people around the world.

Remdesivir was developed by Gilead Sciences and the company has already donated 1.5 million doses, free of charge, for treatment of the seriously ill. But it should be understood that this is no overnight achievement. Remdesivir has actually been in development for over ten years.

John F. Cogan and George P. Schultz, senior fellows at the Stanford Hoover Institution, tell us in The Wall Street Journal this drug treatment breakthrough is a product of the American market and legal system. In this system, privately owned biotech and pharmaceutical companies, financed by investor capital, seek to invent, develop and distribute new medications. Patent protection provides drug companies with additional incentives over and above those normally provided by the market to undertake the necessary risks. The incentives come from governmental protection of intellectual property and the associated ability temporarily to charge prices above the marginal cost of production. Even so, drug companies and their investors reap rewards from their successes, and suffer losses when their efforts fail.

Developing new drugs is a risky and expensive business. About 70% of drugs never make it to market because they prove ineffective or too toxic. Drugs typically gain approval only after many years of development. Charging more than the cost of production, at a price customers are willing to pay, allows developers to recoup these costs.

Over ten years ago, remdesivir was determined to be effective as an antiviral drug. Research of the drug as a treatment for childhood respiratory diseases has been done since 2010. Ultimately, it failed in that purpose, but it was tested in other viral illnesses including Ebola virus and two other corona viruses, SARS and MERS. However, with the passage of those illnesses, there were insufficient patient numbers for human trials of the drug.

Now, remdesivir is back in the news and the most exciting new treatment of Covid-19 yet. But its approval for this new application comes after over ten years of research and development. That’s ten years of expensive R & D, only possible in the American system that permits companies like Gilead to temporarily set prices above the cost of production in normal times, thus enabling the development and donation of this potent treatment now.

Politicians from both political parties have railed against the pharmaceutical companies for over-pricing their drugs. Progressives, like Senator Bernie Sanders, have called for drug price-controls as part of a government-controlled healthcare system. President Trump has also made proposals that would tag the price of drugs in this country to the prices paid in European countries. While these proposals are politically popular, such changes in the current system would seriously hamper our ability to develop new drug treatments at times of national and world-wide crisis such as this Covid-19 pandemic.

It’s a good thing we don’t have government-controlled healthcare, yet.